Partnerships have become crucial in helping people transition out of correction facilities with SUD treatment. For example, substance use disorder provider Groups Recover Together has partnered with several state correctional departments, including Indiana and Maine’s department of corrections (DOC), to provide transitional care and reentry services for individuals transitioning out of incarceration.
Author: Bridge Therapeutics
Bridge Therapeutics, today said that the MAT Act removes the outdated registration requirements on buprenorphine, making it possible for providers nationwide to prescribe it as they would any other controlled medication. Buprenorphine is a partial agonist or partial-acting opioid that treats addiction and chronic pain more safely than full-agonist opioids like morphine, oxycodone and fentanyl.
Treatment for opioid use disorder is limited by there not being enough people that offer medications for opioid use disorder,” said Brian Hurley, MD, MBA, president-elect of the American Society of Addiction Medicine (ASAM). “Removal of the X waiver opens up the capability of prescribing to a much broader group of clinicians.
What happens when a patient who is prescribed buprenorphine undergoes surgery? Experts say they should continue the medication, predominantly prescribed for opioid use disorder, throughout the entire perioperative period. It doesn’t need to be stopped, Lynn Kohan, MD, the medical director of the Pain Management Center told Pain Medicine News.
Bridge Therapeutics is delighted to announce that it achieved a Bronze Award on the Pepperdine Graziadio Business School’s fifth annual Most Fundable Companies® List. Bridge Therapeutics competed against over 4,000 of early-stage US companies to be named one of 16 finalists.
Bridge Therapeutics announced today that they were selected as one of the Top 100 startups to compete and participate in the 9th Annual Startup of the Year Summit. “The Startup of the Year competition is a great way to showcase our innovative approach to treating opioid addiction and chronic pain,” says Dr. Greg Sullivan, founder and Chief Science Officer at Bridge Therapeutics.
“A great part of the tragedy of this opioid crisis is that, unlike in previous such crises America has seen, we now possess effective treatment strategies that could address it and save lives,” Nora Volkow, MD, the director of the National Institute on Drug Abuse, wrote in an editorial accompanying the study (Ann Intern Med 2018…
As President Trump promises to fight the opioid epidemic, here are 14 things experts want him to know Greg Sullivan, MD, Chief Scientific Officer & CEO of Bridge Therapeutics, recently spoke with Managed Healthcare Executive for a special report entitled, “Fourteen things Trump needs to know about opioids.” Managed Healthcare Executive is read by 40,000…
CEO Dr. Greg Sullivan to introduce Bridge and its investigational drug BT-205 to investors and industry executives (PRNewswire) — Bridge Therapeutics, Inc., an innovative development-stage specialty pharmaceutical company, announced that its CEO and Chief Scientific Officer Greg Sullivan, MD, presented at BioTrinity 2017 in London on Thursday, May 11. BioTrinity is Europe’s leading biopartnering and investment conference…